Dendritic cells generated in clinical grade bags strongly differ in immune functionality when compared with classical DCs generated in plates

Journal of Immunotherapy

Volumn 33, Issue 4, 2010, Pages 352-363

  Rouas, Rédouane ^a   Akl, Haidar ^a   Fayyad Kazan, Hussein ^a   Zein, Nabil El ^a   Badran, Bassam ^a   Nowak, Bérangère ^a   Duvillier, Hugues ^a   Martiat, Philippe ^a   Lewalle, Philippe ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Bags or plates; Dendritic cells generation and maturation; Functionality

Indexed keywords

ANTIGEN; BETA CATENIN; CD14 ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; MITOGEN ACTIVATED PROTEIN KINASE;

ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CELL POPULATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DOWN REGULATION; ELECTROPHORETIC MOBILITY; FLOW CYTOMETRY; GENE CONTROL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MICROARRAY ANALYSIS; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; T LYMPHOCYTE; WESTERN BLOTTING;

EID: 85027953773     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181cc266b     Document Type: Article

References (67)

1. Jeras M, Bergant M, Repnik U. In vitro preparation and functional assessment of human monocyte-derived dendritic cells-potential antigen-specific modulators of in vivo immune responses. Transpl Immunol. 2005;14:231-244.
2. O'Neill DW, Bhardwaj N. Exploiting dendritic cells for active immunotherapy of cancer and chronic infections. Mol Biotechnol. 2007;36:131-141.
3. Melief CJ. Cancer immunotherapy by dendritic cells. Immunity. 2008;29:372-383.
4. Duncan C, Roddie H. Dendritic cell vaccines in acute leukaemia. Best Pract Res Clin Haematol. 2008;21:521-541.
5. Dauer M, Schnurr M, Eigler A. Dendritic cell-based cancer vaccination: quo vadis? Expert Rev Vaccines. 2008;7:1041-1053.
6. Chan CW, Housseau F. The "kiss of death" by dendritic cells to cancer cells. Cell Death Differ. 2008;15:58-69.
7. Bendle GM, Holler A, Downs AM, et al. Broadly expressed tumour-associated proteins as targets for cytotoxic T lymphocyte-based cancer immunotherapy. Expert Opin Biol Ther. 2005;5:1183-1192.
8. Pittet MJ. Behavior of immune players in the tumor microenvironment. Curr Opin Oncol. 2009;21:53-59.
9. Rezvani K, Brenchley JM, Price DA, et al. T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin Cancer Res. 2005;11(24 Pt 1):8799-8807.
10. Forsberg O, Carlssön B, Malmstrom PU, et al. High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals. Prostate. 2009;69:70-81.
11. McKee MD, Fichera A, Nishimura MI. T cell immunotherapy. Front Biosci. 2007;12:919-932.
12. Roback JD. Vaccine-enhanced donor lymphocyte infusion (veDLI). Hematology (Am Soc Hematol Educ Program). 2006;1:486-491, 513.
13. Rezvani K, Barrett AJ. Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation. Best Pract Res Clin Haematol. 2008;21:437-453.
14. Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8:299-308.
15. Gattinoni L, Powell DJ Jr, Rosenberg SA, et al. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006;6:383-393. Review.
16. Klebanoff CA, Gattinoni L, Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev. 2006;211:214-224.
17. Hinrichs CS, Gattinoni L, Restifo NP. Programming CD8+ T cells for effective immunotherapy. Curr Opin Immunol. 2006;18:363-370. [Epub April 17, 2006].
18. Reiner SL. Inducing the T cell fates required for immunity. Immunol Res. 2008;42:160-165.
19. Inokuma M, dela Rosa C, Schmitt C, et al. Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature. J Immunol. 2007;179:2627-2633.
20. Giermasz AS, Urban JA, Nakamura Y, et al. Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines. Cancer Immunol Immunother. 2009;58:1329-1336.
21. Dohnal AM, Luger R, Paul P, et al. CD40 ligation restores type 1 polarizing capacity in TLR4 activated dendritic cells that have ceased interleukin-12 expression. J Cell Mol Med. 2008. [Epub ahead of print]
22. Mailliard RB, Wankowicz-Kalinska A, Cai Q, et al. Aalphatype-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 2004;64:5934-5937.
23. Schulz O, Edwards AD, Schito M, et al. CD40 triggering of heterodimeric IL-12p70 production by dendritic cells in vivo requires a microbial priming signal. Immunity. 2000;13:453-462.
24. Onaitis MW, Kalady MF, Emani S, et al. CD40 ligand is essential for generation of specific cytotoxic T cell responses in RNA-pulsed dendritic cell immunotherapy. Surgery. 2003;134:300-305.
25. Mackey MF, Gunn JR, Maliszewsky C, et al. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J Immunol. 1998;161:2094-2098.
26. Kalinski P, Schuitemaker JH, Hilkens CM, et al. Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells. J Immunol. 1999;162:3231-3236.
27. Boullart AC, Aarntzen EH, Verdijk P, et al. Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunol Immunother. 2008;57:1589-1597.
28. Sanarico N, Ciaramella A, Sacchi A, et al. Human monocytederived dendritic cells differentiated in the presence of IL2 produce proinflammatory cytokines and prime Th1 immune response. J Leukoc Biol. 2006;80:555-562.
29. Hilkens CM, Kalinski P, de Boer M, et al. Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. Blood. 1997;90:1920-1926.
30. de Vries IJ, Adema GJ, Punt CJ, et al. Phenotypical and functional characterization of clinical-grade dendritic cells. Methods Mol Med. 2005;109:113-126.
31. Nicolette CA, Healey D, Tcherepanova I, et al. Dendritic cells for active immunotherapy: optimizing design and manufacure in order to develop commercially and clinically viable products. Vaccine. 2007;25S: B47-B60.
32. Elias M, van Zanten J, Hospers GA, et al. Closed system generation of dendritic cells from a single blood volume for clinical application in immunotherapy. J Clin Apheresis. 2005;20:197-207.
33. Meyer-Wentrup F, Burdach S. Efficacy of dendritic cell generation for clinical use: recovery and purity of monocytes and mature dendritic cells after immunomagnetic sorting or adherence selection of CD14+ starting populations. J Hematother Stem Cell Res. 2003;12:289-299.
34. Jarnak-Jankovic S, Hammerstad H, Saeboe-Larssen S, et al. A full scale comparative study of methods for generation of functional dendritic cells for use as cancer vaccines. BMC Cancer. 2007;7:119.
35. Macke L, Wrobel B, Meyring W, et al. Comparison of flask and bag systems in cultivation of dendritic cells for clinical application. In: Smith R, eds. Cell Technology for Cell Products. 2007:239-242.
36. Berger TG, Strasser E, Smith R, et al. Efficient elutriation of monocytes within a closed system (Elutra) for clinicalscale generation of dendritic cells. J Immunol Methods. 2005;298:61-72.
37. [Erratum in: J Immunol Methods. 2005;303:152].
38. Curti A, Isidori A, Ferri E, et al. Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. Leuk Lymphoma. 2004;45:1419-1428.
39. Sorg RV, Ozcan Z, Brefort T, et al. Clinical-scale generation of dendritic cells in a closed system. J Immunother. 2003;26:374-383.
40. Zobywalski A, Javorovic M, Frankenberger B, et al. Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J Transl Med. 2007;5:18.
41. Buchler T, Kovárová L, Musilová R, et al. Generation of dendritic cells using cell culture bags-description of a method and review of literature. Hematology. 2004;9:199-205.
42. Adamson L, Palmborg A, Svensson A, et al. Development of a technology platform for large-scale clinical grade production of DC. Cytotherapy. 2004;6:363-371.
43. Guyre CA, Fisher JL, Waugh MG, et al. Advantages of hydrophobic culture bags over flasks for the generation of monocyte-derived dendritic cells for clinical applications. J Immunol Methods. 2002;262:85-94.
44. Kurlander RJ, Tawab A, Fan Y, et al. A functional comparison of mature human dendritic cells prepared in fluorinated ethylene-propylene bags or polystyrene flasks. Transfusion. 2006;46:1494-1504.
45. Bernard J, Ittelet D, Christoph A, et al. Adherent-free generation of functional dendritic cells from purified blood monocytes in view of potential clinical use. Hematol Cell Ther. 1998;40:17-26.
46. Suen Y, Lee SM, Aono F, et al. Comparison of monocyte enrichment by immuno-magnetic depletion or adherence for the clinical-scale generation of DC. Cytotherapy. 2001;3:365-375.
47. Wong EC, Lee SM, Hines K, et al. Development of a closedsystem process for clinical-scale generation of DCs: evaluation of two monocyte-enrichment methods and two culture containers. Cytotherapy. 2002;4:65-76.
48. Pullarkat V, Lau R, Lee SM, et al. Large-scale monocyte enrichment coupled with a closed culture system for the generation of human dendritic cells. J Immunol Methods. 2002;267:173-183.
49. Erdmann M, Dorrie J, Schaft N, et al. Effective clinical-scale production of dendritic cell vaccines by monocyte elutriation directly in medium, subsequent culture in bags and final antigen loading using peptides or RNA transfection. J Immunother. 2007;30:663-674.
50. Dohnal AM, Graffi S, Witt V, et al. Comparative evaluation of techniques for the manufacturing of dendritic cell-based cancer vaccines. J Cell Mol Med. 2009;13:125-135.
51. Cao H, Verge V, Baron C, et al. In vitro generation of dendritic cells from human blood monocytes in experimental conditions compatible for in vivo cell therapy. J Hematother Stem Cell Res. 2000;9:127-128.
52. Badran BM, Wolinsky SM, Burny A, et al. Identification of three NFAT binding motifs in the 50-upstream region of the human CD3gamma gene that differentially bind NFATc1, NFATc2, and NF-kappa B p50. J Biol Chem. 2002;277:47136-47148.
53. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high-density oligonucleotide array probe level data. Biostatistics. 2003;4:249-264.
54. Simon R, Lam A, Li MC, et al. Analysis of gene expression data using BRB-array tools. Cancer Inform. 2007;2:11-17.
55. Jiang A, Bloom O, Ono S, et al. Disruption of E-cadherinmediated adhesion induces a functionally distinct pathway of dendritic cell maturation. Immunity. 2007;27:610-624.
56. Radons J, Gabler S, Wesche Het, et al. Identification of essential regions in the cytoplasmic tail of interleukin-1 receptor accessory protein critical for interleukin-1 signaling. J Biol Chem. 2002;277:16456-16463.
57. Adib-Conquy M, Cavaillon JM. Gamma interferon and granulocyte/monocyte colony-stimulating factor prevent endotoxin tolerance in human monocytes by promoting interleukin-1 receptor-associated kinase expression and its association to MyD88 and not by modulating TLR4 expression. J Biol Chem. 2002;277:27927-27934.
58. Elkord E, Williams PE, Kynaston H, et al. Human monocyte isolation methods influence cytokine production from in vitro generated dendritic cells. Immunology. 2005;114:204-212.
59. Lehner M, Morhart P, Stilper A, et al. Functional characterization of monocyte-derived dendritic cells generated under serumfree culture conditions. Immunol Lett. 2005;99:209-216.
60. Peggs KS, Mackinnon S. Clinical trials with CMV-specific T cells. Cytotherapy. 2002;4:21-28.
61. Martin M, Schifferle RE, Cuesta N, et al. Role of the phosphatidylinositol 3 kinase-Akt Pathway in the regulation of IL10 and IL-12 by Porphyromonas gingivalis lipopolysaccharide. J Immunol. 2003;171:717-725.
62. Masashi O, Shigenori N, Shuhei K, et al. mTOR and GSK3 differentially regulate LPS-induced IL-12 production in dendritic cells. Blood 2008;112:635-643.
63. Tang N, Liu L, Kang K, et al. Inhibition of monocytic interleukin-12 production by Candida albicans via selective activation of Erk mitogen-activated protein kinase. Infect Immun. 2004;72:2513-2520.
64. Xie J, Qian J, Yang J, et al. Critical roles of Raf/MEK/ERK and PI3K/AKT signaling and inactivation of p38MAP kinase in the differentiation and survival of monocyte-derived immature dendritic cells. Exp Hematol. 2005;33:564-572.
65. Goodridge HS, Harnett W, Liew FY, et al. Differential regulation of interleukin-12 p40 and p35 induction via Erk mitogen-activated protein kinase-dependent and-independent mechanisms and the implications for bioactive IL-12 and IL23 responses. Immunology. 2003;109:415-425.
66. Yu Q, Kovacs C, Yue FY, et al. The role of the p38 mitogenactivated protein kinase, extracellular signal-regulated kinase, and phosphoinositide-3-OH kinase signal transduction pathways in CD40 ligand-induced dendritic cell activation and expansion of virus-specific CD8 T-cell memory responses. J Immunol. 2004;172:6047-6056.
67. Agrawal A, Dillon S, Denning TL, et al. Erk1-/-mice exhibit Th1 cell polarization and increased susceptibility to experimental autoimmune encephalomyelitis. J Immunol. 2006;176:5788-5796.